Search results
Showing 16 to 30 of 140 results for radiofrequency ablation
Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation. This involves using heat to destroy selected areas of the heart to prevent the abnormal electrical impulses responsible for atrial fibrillation.
View recommendations for HTG186Show all sections
Sections for HTG186
Radiofrequency ablation for colorectal liver metastases (HTG208)
Evidence-based recommendations on radiofrequency ablation for the treatment of colorectal liver metastases. This involves using heat to destroy cancer cells in the liver.
View recommendations for HTG208Show all sections
Sections for HTG208
Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids (HTG572)
Evidence-based recommendations on transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids in adults. This involves inserting a device through the cervix into the womb to destroy the fibroid using radiofrequency energy.
View recommendations for HTG572Show all sections
Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia. This involves using heat to destroy selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.
View recommendations for HTG187Show all sections
Sections for HTG187
Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery (HTG72)
Evidence-based recommendations on radiofrequency ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat to interrupt abnormal electrical signals.
View recommendations for HTG72Show all sections
Sections for HTG72
Evidence-based recommendations on radiofrequency ablation of hepatocellular carcinoma. This involves using heat to destroy the part of the liver that contains the cancer.
View recommendations for HTG1Show all sections
Sections for HTG1
Evidence-based recommendations on radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. This involves inserting a needle-like probe containing an electrode into the spinal metastases. This produces an electrical current that aims to relieve pain and other symptoms.
View recommendations for HTG670Show all sections
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction (HTG731)
Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for malignant biliary obstruction. This involves using heat energy to unblock the obstruction.
View recommendations for HTG731Show all sections
In development Reference number: GID-IPG10067 Expected publication date: TBC
Percutaneous radiofrequency ablation for primary or secondary lung cancers (HTG244)
Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.
View recommendations for HTG244Show all sections
Sections for HTG244
Radiofrequency cold ablation for respiratory papillomatosis (HTG295)
Evidence-based recommendations on radiofrequency cold ablation for respiratory papillomatosis. This involves using an electrical current to dissolve or shrink the papillomas (non-cancerous growths).
View recommendations for HTG295Show all sections
Sections for HTG295
This guideline covers diagnosing and managing varicose veins in people aged 18 and over. It aims to ensure that people understand the options for treating varicose veins and that healthcare professionals know when to refer people for specialist assessment and treatment.
This quality standard covers diagnosing and managing varicose veins in the legs of adults (aged 18 and over). It includes referral for specialist assessment and treatment options. It describes high-quality care in priority areas for improvement.
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)
This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatments are used.